Ipsen develops and manufactures a range of pharmaceutical products primarily focused on three key therapeutic areas: oncology, rare diseases, and neuroscience.
Ipsen's product portfolio includes innovative medicines designed to address significant unmet medical needs across various specialized therapeutic areas. Their commitment to these fields is reflected in their key products, which include treatments for cancer, rare genetic disorders, and neurological conditions.
Here is a breakdown of some of Ipsen's key pharmaceutical products:
| Therapeutic Area | Brand Name | Generic Name (Active Ingredient) |
|---|---|---|
| Oncology | Somatuline Autogel® | lanreotide injection |
| Oncology | Onivyde® | irinotecan liposome injection |
| Rare Disease | Sohonos® | palovarotene |
| Rare Disease | Increlex® | mecasermin |
| Neuroscience | Dysport® | abobotulinumtoxinA |
These products demonstrate Ipsen's strategic focus on bringing targeted therapies to patients in need. For more detailed information about their pipeline and full product offerings, you can visit the official Ipsen website.
